Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Actavis; Forest Laboratories
- 18 Oct 2022 Results assessing efficacy, safety, and tolerability of cariprazine for relapse prevention in adults with schizophrenia, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology.
- 18 Oct 2022 According to a Gedeon Richter media release, results from this trial were presented during the 35th Annual Meeting of the European College of Neuropsychopharmacology (ECNP) 2022.
- 18 Oct 2022 Results published in the Gedeon Richter Media Release.